Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cidabenamine Combined With Azacitidine for Preventing Progression in High-Risk PTCL After Allo-HSCT
NCT07389616Phase 3Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Feb 2026
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cidabenamine in peripheral T-cell lymphoma (PTCL), sponsored by Shanghai General Hospital. Started Feb 2026; status: recruiting.
02
Drugs
cidabenamine
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT07389616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07389616.